Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: Alternative retinoblastoma treatment

Biomedical Papers

Volumn 156, Issue 4, 2012, Pages 318-323

  Darsova, Denisa ^a   Pochop, Pavel ^a   Uhlik, Jiri ^b   Klapkova, Eva ^a   Tesfaye, Hundie ^a   Kodetova, Daniela ^a   Lestak, Jan ^c   Malis, Josef ^a   Vajner, Ludek ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Department of Ophthalmology   (Czech Republic)

Author keywords

Intravitreal drug delivery; Intravitreal seeding; Periocular injection; Retinoblastoma; Topotecan

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; RABBIT; RETINA; RETINA TUMOR; RETINOBLASTOMA; VITREOUS BODY;

ANIMALS; RABBITS; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; TOPOISOMERASE I INHIBITORS; TOPOTECAN; VITREOUS BODY;

ORYCTOLAGUS CUNICULUS;

EID: 84872028310     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2011.068     Document Type: Article

References (21)

1. Baráková D. Retinoblastom. In: Baráková D, editor. Nádory oka. Praha: Grada; 2002. p.132-49.
2. Řehůřek J, Autrata R. Retinoblastom. In: ADAM, Z. ¬ VORLÍČEK J et al. Speciální onkologie. Brno: Masarykova univerzita v Brně; 2002. p.261-2.
3. Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 2004;24:849-62.
4. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657-64.
5. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmol 1999;106:1947-50.
6. Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M, Feuer WJ, Hernandez E, Parel JM. Pharmacokinetics of Systemic Versus Focal Carboplatin Chemotherapy in the Rabbit Eye: Possible Implication in the Treatment of Retinoblastoma. Invest Ophthalmol Vis Sci 2004;45:3644-9.
7. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular Concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116:1209-12.
8. Pochop P, Darsova D, Kukacka J, Tesfaye H; Vajner L, Uhlik J, Kodetova D, Malis J, Dotrelova D. Intravitreal carboplatin concentration and area under concentration versus time curve after intravitreal and periocular delivery. Europ J Ophthalmol 2010;20:745-51.
9. Schmack I, Hubbard GB, Kang SJ, Aaberg TM, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006;142:310-15.
10. Abramson DH. Periocular chemotherapy for retinoblastoma: success with problems?. Arch Ophthalmol 2005;123:128-9.
11. Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-20.
12. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
13. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ, Stewart CF. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-40.
14. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt CH. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol 2002;20:1617-24.
15. Chantada GL, Fandiñ AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004;25:37-43.
16. Carcaboso AM, Bramuglia GF, Chantada GL, Fandiño AC, Chiappetta DA, de Davila MTG, Rubio MC, Abramson DH. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci 2007;48:3761-7.
17. Tsui JY, Dalgard C, Van Quill KR, Lee L, Grossniklaus HE, Edelhauser HF, O'Brien JM. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthal Vis Sci 2008;49:490-6.
18. Buitrago E, Höcht CH, Fandiño AC, Navo E, Abramson DH, Schaiquevich P, Bramuglia G. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. Exp Eye Res 2010;91:9-14.
19. Saravanan G, Suryanarayana MV, Balaji N, Someswararao N, Sekhar NM. A stability-Indicating LC method for assay of topotecan hydrochloride. Chromatogr 2008;67:179-82.
20. Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Can Res 2005;11:7569-78.
21. Pardue MT, Hejny C, Gilbert JA, Philips MJ, Geroski DH, Edelhauser HF. Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina 2004;24:776-82.